Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Integrity Partners Group
WARNING LETTER
•Integrity Partners Group•June 24, 2025

Integrity Partners Group – FDA Warning Letter, Jun 24, 2025

Record Details

The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Integrity Partners Group, following an inspection of its drug manufacturing facility, Chemisphere Corporation, from June 16 to 24, 2025. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations, rendering the company"s drug products adulterated. Key issues identified include the failure to perform essential laboratory testing on finished drug products before release. Specifically, the company did not adequately test over-the-counter (OTC) drug products for the strength of active ingredients or for microbiological contamination. This lack of testing means the company could not ensure products met quality specifications. Furthermore, the company failed to verify the identity of raw materials and high-risk components, such as glycerin, used in manufacturing. It relied on supplier certificates of analysis without proper validation, missing critical tests for hazardous impurities like diethylene glycol (DEG) and ethylene glycol (EG). The FDA deemed the company"s responses to these observations inadequate. Required actions include a comprehensive independent assessment of laboratory practices and a detailed plan to remediate and evaluate the effectiveness of the laboratory system. Integrity Partners Group must also conduct a thorough review of its material system, including supplier qualification and component testing. This involves establishing robust chemical and microbiological quality control specifications for all incoming materials and testing reserve samples of distributed products to ensure quality, with a mandate for rapid corrective actions, including recalls, if deficiencies are found.

Company
Integrity Partners Group
Inspection date
June 24, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Darren J. Birkelbach
View Company Profile

ID · da552bf0-e680-4f1b-8b93-085f7a306c4a

Violation Codes10
21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.165(a)21 CFR 211.165(b)21 CFR 211.84(d)(1)21 CFR 211.84(d)(2)21 CFR 211.67(b)21 CFR 211.100(a)21 CFR 211.34

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Integrity Partners Group
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.